has course role

• BCC7110 Medicine Clerkship
• BCC7111 Senior Medicine Clerk
• BMS6300C Med Micrbio/infec Dis
• BMS6834 Essen Patient Care 4
• GMS6905 Independent Studies
• GMS6910 Supervised Research
• GMS6971 Masters Research
• GMS7093 Intro Clin/tran Rsch
• GMS7980 Doctoral Research
• MEL7948 Elect Top/medicine
• PAS5160 Gastroenterology

member of

• CTSA Consortium Steering Committee Member 2010 -
• American Association for the Study of Liver Diseases Member 1994 -
• American Gastroenterological Association Member 1993 -

selected publications

• academic article

  • Treatment Outcomes and Prognostic Factors of Intrahepatic Cholangiocarcinoma.  Oncology Reports.  29:1259-1267. 2013-04-01
  • New Therapeutic Strategies in Hcv: Second-Generation Protease Inhibitors.  Liver International.  33:80-84. 2013-02-01
  • Cc Genotype Donors for the Interleukin-28B Single Nucleotide Polymorphism Are Associated With Better Outcomes in Hepatitis C After Liver Transplant.  Liver International.  33:72-78. 2013-01-01
  • Opa1 Downregulation Is Involved in Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma.  Laboratory Investigation.  93:8-19. 2013-01-01
  • The Anti-Viral Effect of Sorafenib in Hepatitis C-Related Hepatocellular Carcinoma.  Alimentary Pharmacology & Therapeutics.  37:91-97. 2013-01-01
  • A 12-Week Interferon-Free Treatment Regimen With Abt-450/R, Abt-267, Abt-333 and Ribavirin Achieves Svr12 Rates (Observed Data) of 99\% in Treatment-Naive Patients and 93\% in Prior Null Responders With Hcv Genotype1 Infection.  Hepatology.  56:1515-1516. 2012-12-01
  • High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (Ns5a Inhibitor) Plus Sofosbuvir (Nucleotide Ns5B Inhibitor), With Or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With Hcv Genotype 1, 2, Or 3.  Hepatology.  56:1516-1517. 2012-12-01
  • Boceprevir (Boc) Combined With Peginterferon Alfa-2B/Ribavirin (P/Rbv) in Treatment-Naive Chronic Hcv Genotype 1 Patients With Compensated Cirrhosis: Sustained Virologic Response (Svr) and Safety Subanalyses From the Anemia Management Study.  Higher Education Policy.  56:216A. 2012-10-01
  • Genome-Wide Association Study To Characterize Potential Determinants of Bilirubin Elevations in Hcv Patients Receiving the Hcv Ns3 Serine Protease Inhibitor Gs-9256.  Higher Education Policy.  56:585A-586A. 2012-10-01
  • Incidentally Discovered Hcc (Ihcc) in Explant Liver- Clinical and Histopathologic Features and Outcome.  Higher Education Policy.  56:476A-477A. 2012-10-01
  • Once Daily Sofosbuvir (Gs-7977) Plus Peg/Rbv: High Early Response Rates Are Maintained During Post-Treatment Follow-Up in Treatment-Naive Patients With Hcv Genotype 1, 4, and 6 Infection in the Atomic Study.  Higher Education Policy.  56:307A. 2012-10-01
  • Serum Levels of Soluble Cd25 as a Marker for Hepatocellular Carcinoma.  Oncology Letters.  4:840-846. 2012-10-01
  • The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma.  Higher Education Policy.  56:458A-459A. 2012-10-01
  • The Safety of Telaprevir in the Absence of Interferon And/Or Ribavirin: Analysis of On-Treatment Data From the Zenith Trial.  Higher Education Policy.  56:574A-575A. 2012-10-01
  • Vx-222, Telaprevir and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C: Results of the Zenith Study Interferon-Free Regimen.  Higher Education Policy.  56:308A. 2012-10-01
  • Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma On Long-Term Outcomes After Liver Transplantation.  American Journal of Clinical Oncology.  35:345-350. 2012-08-01
  • Levels of Alanine Aminotransferase Confound Use of Transient Elastography To Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection.  Clinical Gastroenterology and Hepatology.  10:932-937. 2012-08-01
  • Unexpected Maintenance of Hepatitis C Viral Diversity Following Liver Transplantation.  Journal of Virology.  86:8432-8439. 2012-08-01
  • Diagnosis and Management of Patients With Alpha(1)-Antitrypsin (A1At) Deficiency.  Clinical Gastroenterology and Hepatology.  10:575-580. 2012-06-01
  • Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS).  Clinical and Translational Science.  5:121-129. 2012
  • Atomic: 97\% Rvr for Psi-7977+Peg/Rbv X 12 Week Regimen in Hcv Gt1: An End To Response-Guided Therapy?.  Journal of Hepatology.  56:S1. 2012-04-01
  • High Svr12 With 16 Weeks of Tegobuvir and Gs-9256 With Peginterferon-Alfa 2a and Ribavirin in Treatment-Naive Genotype 1 Hcv Patients.  Journal of Hepatology.  56:S6-S7. 2012-04-01
  • Peginterferon Lambda-1a (Lambda) Compared To Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With Hcv Genotypes (G) 2 Or 3: First Svr24 Results From Emerge Phase Iib.  Journal of Hepatology.  56:S5-S6. 2012-04-01
  • Potent Viral Suppression With All-Oral Combination of Daclatasvir (Ns5a Inhibitor) and Gs-7977 (Ns5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic Hcv Gt1, 2, Or 3.  Journal of Hepatology.  56:S560. 2012-04-01
  • Psi-7977 400 Mg Qd Safety and Tolerability in the First 450 Patients Treated for 12 Weeks.  Journal of Hepatology.  56:S441. 2012-04-01
  • Psi-7977 Proton and Electron: 100\% Concordance of Svr4 With Svr24 in Hcv Gt1, Gt2, and Gt3.  Journal of Hepatology.  56:S4. 2012-04-01
  • An Update On Treatment of Hepatitis C Virus Genotype 1 Infection and Viral Load Assessments Reply.  Higher Education Policy.  55. 2012-03-01
  • The Role of Ribavirin in Direct Acting Antiviral Drug Regimens for Chronic Hepatitis C.  Liver International.  32:103-107. 2012-02-01
  • Liver test results do not identify liver disease in adults with alpha-1 antitrypsin deficiency.  Clinical Gastroenterology and Hepatology.  10:1278-1283. 2012
  • Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008.  BMC Research Notes.  142. 2012
  • Balapiravir Plus Peginterferon Alfa-2a (40Kd)/Ribavirin in a Randomized Trial of Hepatitis C Genotype 1 Patients.  Annals of Hematology.  11:15-31. 2012-01-01
  • Viral Clearance Is Associated With Improved Insulin Resistance in Genotype 1 Chronic Hepatitis C But Not Genotype 2/3.  Gut.  61:128-134. 2012-01-01
  • University of Florida Clinical and Translational Science Institute: Transformation and Translation in Personalized Medicine.  Clinical and Translational Science.  4:400-402. 2011
  • Antiviral Effect of Sorafenib in Hcv Related Hepatocellular Carcinoma.  Higher Education Policy.  54:1422A. 2011-10-01
  • Identification of the Ifitm3 Gene as An Inhibitor of Hepatitis C Viral Translation in a Stable Stat1 Cell Line.  Journal of Viral Hepatitis.  18:E523-E529. 2011-10-01
  • Klatskin Tumor- Clinical Outcome and Prognostic Factors.  Higher Education Policy.  54:1372A. 2011-10-01
  • Once-Daily Psi-7977 Plus Peg/Rbv in Treatment-Naive Patients With Hcv Gt1: Robust End of Treatment Response Rates Are Sustained Post-Treatment.  Higher Education Policy.  54:472A-473A. 2011-10-01
  • Sustained Virologic Response (Svr) in American Naive Mono-Infected Chronic Hepatitis C (Chc) Patients (Pts) Treated With Peginterferon Alfa (Pegifn Alpha) Plus Ribavirin (Rbv): Final Analysis of the Large, Multinational Real-World Prophesys Database.  Higher Education Policy.  54:865A-866A. 2011-10-01
  • Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated With a Telaprevir-Based Regimen Regardless of Liver Fibrosis Stage.  Higher Education Policy.  54:1348A. 2011-10-01
  • Vx-222/Telaprevir in Combination With Peginterferon-Alfa-2a and Ribavirin in Treatment-Naive Genotype 1 Hcv Patients Treated for 12 Weeks: Zenith Study, Svr12 Interim Analysis.  Higher Education Policy.  54:1435A. 2011-10-01
  • Expression of An Irf-3 Fusion Protein and Mouse Estrogen Receptor, Inhibits Hepatitis C Viral Replication in Rig-I-Deficient Huh 7.5 Cells.  Virology Journal.  8:445. 2011-09-01
  • Is Model for End-Stage Liver Disease Score Associated With Quality of Life After Liver Transplantation?.  Progress in transplantation official publication, North American Transplant Coordinators Organization.  21:207-214. 2011-09-01
  • Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection.  New England Journal of Medicine.  365:1014-1024. 2011-09-01
  • Steatosis Is An Independent Predictor of Relapse Following Rapid Virologic Response in Patients With Hcv Genotype 3.  Clinical Gastroenterology and Hepatology.  9:688-693. 2011-08-01
  • Racial differences in hepatitis C treatment eligibility Hepatology.  Hepatology.  54:70-78. 2011
  • The Combination of Sorafenib With Transarterial Chemoembolisation for Hepatocellular Carcinoma.  Alimentary Pharmacology & Therapeutics.  34:205-213. 2011-07-01
  • Characterization of Hcv Interactions With Toll-Like Receptors and Rig-I in Liver Cells.  PLoS One.  6. 2011-06-01
  • Health and Functional Status for Individuals With Thrombocytopenia in the United States: Evidence From Nhanes.  Value in Health.  14:A72. 2011-05-01
  • Phoenix: a Randomized Controlled Trial of Peginterferon Alfa-2a Plus Ribavirin as a Prophylactic Treatment After Liver Transplantation for Hepatitis C Virus.  Liver Transplantation.  17:528-538. 2011-05-01
  • Kinase Inhibitor Sorafenib Modulates Immunosuppressive Cell Populations in a Murine Liver Cancer Model.  Modern pathology.  91:598-608. 2011-04-01
  • 24-Week Treatment With Cts-1027 in Combination With Ribavirin Reduces Hcv-Rna in Treatment Naive Genotype-1 Patients.  Journal of Hepatology.  54:410. 2011-03-01
  • A Sustained Viral Response Dramatically Improves Survival in Patients With Hepatitis C Infection After Liver Transplant.  Journal of Hepatology.  54:537. 2011-03-01
  • Alt Abnormalities in Adults With Alpha-1 Antitrypsin Deficiency.  Journal of Hepatology.  54:890. 2011-03-01
  • Once Daily Psi-7977 Plus Peg-Ifn/Rbv in Hcv Gt1: 98\% Rapid Virologic Response, Complete Early Virologic Response: the Proton Study.  Journal of Hepatology.  54:1372. 2011-03-01
  • Once Daily Psi-7977 Plus Pegifn/Rbv in a Phase 2B Trial: Rapid Virologic Suppression in Treatment-Naive Patients With Hcv Gt2/Gt3.  Journal of Hepatology.  54:61. 2011-03-01
  • Pegylated Interferon-Lambda (Pegifn-Lambda) Shows Superior Viral Response With Improved Safety and Tolerability Versus Pegifn Alpha-2a in Hcv Patients (G1/2/3/4): Emerge Phase Iib Through Week 12.  Journal of Hepatology.  54:1360. 2011-03-01
  • Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-Naive Patients Regardless of Race Or Ethnicity.  Journal of Hepatology.  54:415. 2011-03-01
  • Vx-222 With Tvr Alone Or in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C: Zenith Study Interim Results.  Journal of Hepatology.  54:1363. 2011-03-01
  • Reactive Oxygen Species Is Essential for Cycloheximide To Sensitize Lexatumumab-Induced Apoptosis in Hepatocellular Carcinoma Cells.  PLoS One.  6. 2011-02-01
  • Using Fotonovelas To Promote Healthy Eating in a Latino Community.  American Journal of Public Health.  101:258. 2011-02-01
  • An Update Of Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline By the American Association for the Study of Liver Diseases.  Hepatology.  54:1433-1444. 2011
  • Boceprevir for untreated chronic HCV genotype 1 infection.  New England Journal of Medicine.  364:1195-1206. 2011
  • Different Radiosensitivity of Cd4(+)Cd25(+) Regulatory T Cells and Effector T Cells To Low Dose Gamma Irradiation in Vitro.  International Journal of Radiation Biology.  87:71-80. 2011-01-01
  • Low Prevalence of Hbv Dna in the Liver Allograft From Anti-Hbc-Positive Donors: a Single-Center Experience.  Clinical Transplantation.  25:164-170. 2011-01-01
  • Pilot Study: Fenofibrate for Patients With Primary Biliary Cirrhosis and An Incomplete Response To Ursodeoxycholic Acid.  Alimentary Pharmacology & Therapeutics.  33:235-242. 2011-01-01
  • The Role of Triple Therapy With Protease Inhibitors in Hepatitis C Virus Genotype 1 Naive Patients.  Liver International.  31:53-57. 2011-01-01
  • Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.  Gastroenterology.  139:1602-1611. 2010
  • Hepatitis C Virus Modulates Human Monocyte-Derived Dendritic Cells.  Journal of Viral Hepatitis.  17:757-769. 2010-11-01
  • Transfusion Has No Effect On Recurrence in Hepatitis C After Liver Transplantation.  Acta Anaesthesiologica Scandinavica.  54:1224-1232. 2010-11-01
  • Veteran Family Reintegration, Primary Care Needs, and the Benefit of the Patient-Centered Medical Home Model.  The journal of the American Board of Family Medicine.  23:770-774. 2010-11-01
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1.  Gastroenterology.  139:1257-1266. 2010
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-? in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3..  Gastroenterology.  139:1267-1276. 2010-10-01
  • Clinical Synergy of An Anti-Hcv Nucleoside Analog With Soc: Viral Kinetics of Psi-7977 With Society.  Higher Education Policy.  52:1861. 2010-10-01
  • Genotype-Specific Predictors of Early Viral Clearance Following Treatment With Peginterferon Alfa-2a (40Kd) (Pegifn Alpha-2A) Plus Ribavirin (Rbv): Multiple Logistic Regression Analysis From the Large Multinational Prophesys Cohorts.  Higher Education Policy.  52:1002. 2010-10-01
  • Hepatitis B Reactivation and Rituximab in the Oncology Practice.  Oncologist.  15:13-21. 2010-10-01
  • Influence of Serum and Soluble Cd25 (Scd25) On Regulatory and Effector T-Cell Function in Hepatocellular Carcinoma.  Scandinavian Journal of Immunology.  72:293-301. 2010-10-01
  • Predictors of Relapse in Genotype 3 Infected Chronic Hcv Patients Who Achieve Rapid Virologic Response.  Higher Education Policy.  52:991. 2010-10-01
  • Safety and Virologic Response Rates in Patients With History of Injection Drug Use (Idu): Pooled Analysis of Data From Four Randomized Phase III Studies of Peginterferon Alfa-2a (40Kd) Plus Ribavirin (Rbv).  Higher Education Policy.  52:1001. 2010-10-01
  • Telaprevir in Combination With Peginterferon Alfa2a and Ribavirin for 24 Or 48 Weeks in Treatment-Naive Genotype 1 Hcv Patients Who Achieved An Extended Rapid Viral Response: Final Results of Phase 3 Illuminate Study.  Higher Education Policy.  52:LB-2. 2010-10-01
  • The Impact of Preservation Injury On Accelerated Hepatitis C Recurrence After Liver Transplantation.  Higher Education Policy.  52:2. 2010-10-01
  • The Impact of Transarterial Therapy in Recurrent Hepatocellular Carcinoma After Liver Transplant.  Higher Education Policy.  52:1753. 2010-10-01
  • Fatigue and Sleep Quality Before and After Liver Transplantation.  Progress in transplantation official publication, North American Transplant Coordinators Organization.  20:221-233. 2010-09-01
  • Identifying Hepatitis C Virus Genotype 2/3 Patients Who Can Receive a 16-Week Abbreviated Course of Peginterferon Alfa-2a (40Kd) Plus Ribavirin.  Hepatology.  51:1897-1903. 2010-06-01
  • New Therapies in the Management of Hepatitis C Virus.  Current Opinion in Gastroenterology.  26:196-201. 2010-05-01
  • Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25)..  Digestive Diseases and Sciences.  55:484-495. 2010-02-01
  • Review Article: the Management of Hepatocellular Carcinoma.  Alimentary Pharmacology & Therapeutics.  31:461-476. 2010-02-01
  • Characterization of anti-HCV antibodies in IL-10-treated patients.  Viral Immunology.  23:359-368. 2010
  • Telaprevir for previously treated chronic HCV infection.  New England Journal of Medicine.  362:1292-1303. 2010
  • Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma..  Scandinavian Journal of Immunology.  72. 2010
  • Transfusion has no effect on recurrence in hepatitis C after liver transplantation..  Acta Anaesthesiologica Scandinavica.  54. 2010
  • Baseline Characteristics Associated With Prescription of Ribavirin > 800 Mg/Day Among G2/3 Patients Prescribed Peginterferon Alfa-2a (40Kd) From Real-World Patient Cohorts: Interim Results From Prophesys.  Journal of Hepatology.  52:S125-S126. 2010-01-01
  • Dynamics of Apoptotic Activity in Patients With Chronic Hepatitis C Treated With Albinterferon Alfa-2B Or Peginterferon Alfa-2a.  Journal of Hepatology.  52:S113. 2010-01-01
  • Evaluating Virologic Response Within 2-4 Weeks Has High Positive/Negative Predictive Values for Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C During Treatment.  Journal of Hepatology.  52:S120. 2010-01-01
  • Longitudinal Prospective Comparison of Fibrosure and Transient Elastography in Relation To Virologic Response: a Substudy of the Phase 3 Albinterferon Alfa-2B Trials.  Journal of Hepatology.  52:S170. 2010-01-01
  • Marked Spirometry Decline in Patients With Chronic Hepatitis C During Treatment With Albinterferon Alfa-2B Is Similar To Peginterferon Alfa-2a.  Journal of Hepatology.  52:S130. 2010-01-01
  • Phase Iib Study of Balapiravir (Rg1626; Nucleoside Analogue Inhibitor of Hcv Polymerase) Plus Peginterferon Alfa-2a (40Kd) and Ribavirin for Chc Genotype 1: Final Results.  Journal of Hepatology.  52:S302-S303. 2010-01-01
  • The Use of Cyclosporine for Recurrent Hepatitis C After Liver Transplant: a Randomized Pilot Study.  Digestive Diseases and Sciences.  55:196-203. 2010-01-01
  • A Randomized Controlled Trial of the Efficacy, Tolerability, and Safety of Prophylactic Treatment With Peginterferon Alfa-2a Plus Ribavirin After Orthotopic Liver Transplantation (Olt) for Hepatitis C: the Phoenix Study.  Higher Education Policy.  50:506. 2009-10-01
  • Anti-Hepatitis C Viral Activities By Inducible Stat1 Activation.  Higher Education Policy.  50:1428. 2009-10-01
  • Efficacy and Safety Results of Albinterferon Alfa-2B in Combination With Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 Or 3.  Higher Education Policy.  50:1567. 2009-10-01
  • Fenofibrate Improves Liver Biochemistries in Primary Biliary Cirrhosis.  Higher Education Policy.  50:1503. 2009-10-01
  • Hepatitis B Viral Dna Seldom Present in the Transplant Liver From Anti-Hbc-Positive Donors.  Higher Education Policy.  50:530. 2009-10-01
  • Hepatitis C Drug Development At a Crossroads.  Higher Education Policy.  50:997-999. 2009-10-01
  • Identifying Hcv Genotype 2/3 Patients Who Could Receive a 16-Week Abbreviated Course of Peginterferon Alfa-2a (40Kd) Plus Ribavirin.  Higher Education Policy.  50:35. 2009-10-01
  • Insulin Resistance and Hepatic Steatosis Are Both Independently Associated With Advanced Hepatic Fibrosis in Chronic Hepatitis C Infection: Analysis of the Achieve 1 and Achieve 2/3 Cohorts.  Higher Education Policy.  50:1622. 2009-10-01
  • Longitudinal Prospective Comparison of Fibrosure and Fibroscan in Relation To Virologic Response in a Phase III Study of Albinterferon Alfa-2B and Ribavirin in Treatment Naive Chc Patients.  Higher Education Policy.  50:1084. 2009-10-01
  • Similar Rates of Interstitial Findings On Chest X-Ray in Hcv Patients Treated With Albinterferon Alfa-2B Or Peginterferon Alfa-2a.  Higher Education Policy.  50:1572. 2009-10-01
  • Sustained Virologic Response 15 Independently Associated With Improvement in Insulin Resistance in Genotype 1, But Not Genotype 2/3, Chronic Hcv Patients.  Higher Education Policy.  50:117. 2009-10-01
  • A Phase III Study of the Safety and Efficacy of Viramidine Versus Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C: Viser1 Results.  Higher Education Policy.  50:717-726. 2009-09-01
  • A Randomized Controlled Trial of Thymalfasin Plus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.  Hepatology International.  3:480-489. 2009-09-01
  • The Natural History of Hepatitis C Cirrhosis After Liver Transplantation.  Liver Transplantation.  15:1063-1071. 2009-09-01
  • Novel Interferons for Treatment of Hepatitis C Virus.  Clinics in Liver Disease.  13:351-363. 2009-08-01
  • Intraoperative Red Cell and Platelet Transfusion Have No Effect On Survival Or Histologic Disease Recurrence in Hepatitis C Patients After Liver Transplantation.  Liver Transplantation.  15:S221. 2009-07-01
  • Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells..  Cell Biology International.  33:565-571. 2009
  • Changes in B-Lymphocyte Stimulator Protein Levels During Treatment With Albinterferon Alfa-2B in Patients With Chronic Hepatitis C Who Have Failed Previous Interferon Therapy.  Hepatology Research.  39:455-462. 2009-05-01
  • Gamma Irradiation Alters the Phenotype and Function of Cd4(+)Cd25(+) Regulatory T Cells.  Cell Biology International.  33:565-571. 2009-05-01
  • Hepatitis C Virus: a Critical Appraisal of Approaches To Therapy.  Clinical Gastroenterology and Hepatology.  7:397-414. 2009-04-01
  • Ribavirin: Current Role in the Optimal Clinical Management of Chronic Hepatitis C.  Journal of Hepatology.  50:402-411. 2009-02-01
  • Safety and Antiviral Activity of Albinterferon Alfa-2B in Prior Interferon Nonresponders With Chronic Hepatitis C.  Clinical Gastroenterology and Hepatology.  7:212-218. 2009-02-01
  • Using An Immune Functional Assay To Differentiate Acute Cellular Rejection From Recurrent Hepatitis C in Liver Transplant Patients.  Liver Transplantation.  15:216-222. 2009-02-01
  • Improving the Standard of Care for HCV Management: Available and Emerging Strategies for Optimal Patient Outcomes.  PeerView.  2009
  • New Therapies cannot get here fast enough 2009
  • PROVE 1: Telapravir with peginterferon and ribavirin for chronic HCV genotype 1 infection.  New England Journal of Medicine.  360:1827-1838. 2009
  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.  New England Journal of Medicine.  361:580-593. 2009
  • Hepatitis C virus: a critical appraisal of approaches to therapy..  Clinical Gastroenterology and Hepatology.  7. 2009
  • Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C..  Clinical Gastroenterology and Hepatology.  7. 2009
  • The natural history of hepatitis C cirrhosis after liver transplantation..  Liver Transplantation.  15. 2009
  • Efficacy and Safety Results of Albinterferon Alfa-2B in Combination With Ribavirin in Interferon-Alfa Treatment Naive Patients With Genotype 2 Or 3 Chronic Hepatitis C.  Journal of Hepatology.  50:1042. 2009-01-01
  • Efficacy and Safety of the Cyclophilin Inhibitor Debio 025 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Previously Null-Responder Genotype 1 Hcv Patients.  Journal of Hepatology.  50:95. 2009-01-01
  • Factors Predicting Survival After Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years' Experience From a Single Tertiary Medical Center.  Journal of Vascular and Interventional Radiology.  19:1576-1581. 2008-11-01
  • Antiviral Activity of the Hcv Nucleoside Polymerase Inhibitor R7128 in Hcv Genotype 2 and 3 Prior Non-Responders: Interim Results of R7128 1500Mg Bid With Peg-Ifn and Ribavirin for 28 Days.  Higher Education Policy.  48:1024A. 2008-10-01
  • High Relapse Rate Seen At Week 72 for Patients Treated With R1626 Combination Therapy.  Higher Education Policy.  48:1349-1350. 2008-10-01
  • Improved Outcomes in Patients With Hepatitis C With Difficult-To-Treat Characteristics: Randomized Study of Higher Doses of Peginterferon Alpha-2a and Ribavirin.  Higher Education Policy.  48:1033-1043. 2008-10-01
  • Is Sonographic Surveillance of Polytetrafluoroethylene-Covered Transjugular Intrahepatic Portosystemic Shunts (Tips) Necessary? a Single Centre Experience Comparing Both Types of Stents.  Clinical Radiology.  63:1142-1148. 2008-10-01
  • Potent Antiviral Response To the Hcv Nucleoside Polymerase Inhibitor R7128 for 28 Days With Peg-Ifn and Ribavirin: Subanalysis By Race/Ethnicity, Weight and Hcv Genotype.  Higher Education Policy.  48:1160A. 2008-10-01
  • Using Immune Functional Assay To Differentiate Acute Cellular Rejection From Recurrent Hepatitis C in Liver Transplant Patients.  Higher Education Policy.  48:555A. 2008-10-01
  • R1626 Plus Peginterferon Alfa-2a Provides Potent Suppression of Hepatitis C Virus Rna and Significant Antiviral Synergy in Combination With Ribavirin.  Higher Education Policy.  48:385-397. 2008-08-01
  • A Cross-Sectional Study of Fatigue Before and After Liver Transplantation.  American Journal of Transplantation.  8:334. 2008-05-01
  • Management of viral hepatitis in hematologic malignancies..  Blood Reviews.  22:117-126. 2008-05-01
  • Meld and Prediction of Quality of Life One-Year After Liver Transplantation..  American Journal of Transplantation.  8:220. 2008-05-01
  • Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients With Hepatitis C.  American Journal of Transplantation.  8:382. 2008-05-01
  • Correlation of Fibrospect Ii With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C.  Clinical Gastroenterology and Hepatology.  6:242-247. 2008-02-01
  • Antiviral Activity and Changes in B-Lymphocyte Stimulator Protein Levels During Treatment With Albinterferon Alfa-2B/Ribavirin in Prior Interferon-Therapy Nonresponders.  Journal of Hepatology.  48:S313. 2008-01-01
  • Cyclosporine Helps To Achieve a Higher Svr in Patients Receiving Peg-Interferon/Ribavirin for Recurrent Hepatitis C After Liver Transplantation: Final Analysis of a Randomized-Controlled Study.  Journal of Hepatology.  48:S82. 2008-01-01
  • Dynamic Evolution of Therapy for Chronic Hepatitis C: How Will Novel Agents Be Incorporated Into the Standard of Care?.  Antiviral Therapy.  13:747-760. 2008-01-01
  • Hepatocellular Carcinoma Is Associated With An Impaired Cd4 T Cell Immune Response.  Journal of Hepatology.  48:S140. 2008-01-01
  • High End-Of-Treatment Response (84\%) After 4 Weeks of R1626, Peginterferon Alfa-2a (40Kd) and Ribavirin Followed By a Further 44 Weeks of Peginterferon Alfa-2a and Ribavirin.  Journal of Hepatology.  48:S371. 2008-01-01
  • Potent Antiviral Activity of the Hcv Nucleoside Polymerase Inhibitor R7128 With Peg-Ifn and Ribavirin: Interim Results of R7128 500Mg Bid for 28 Days.  Journal of Hepatology.  48:S29. 2008-01-01
  • Ribavirin Considerations in Treatment Optimization.  Antiviral Therapy.  13:23-30. 2008-01-01
  • The Natural History of Hcv-Related Cirrhosis After Liver Transplantation.  Journal of Hepatology.  48:S3. 2008-01-01
  • The Failing Liver.  Gastroenterology.  21. 2007
  • 16 vs 24 weeks of peginterferon alfa-2a plus ribavirin for patients with HCV genotypes 2 or 3 infection.  New England Journal of Medicine.  357:176-178. 2007
  • Anti-HCV activity of albinterferon alfa-2b in cell culture.  Hepatology Research.  37:941-947. 2007
  • Final Results of A Double-Blind, Placebo-Controlled Trial of the Antifibrotic Efficacy of Interferon-gamma 1b in Chronic Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.  Hepatology.  45:569-578. 2007
  • Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.  Gastroenterology.  133:1649-1659. 2007
  • Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells.  Laboratory Investigation.  87:582-590. 2007
  • New Inhibitors of the HCV Life Cycle.  Hot Topics in Viral Hepatitis.  7-13. 2007
  • The financial burden of transplantation: a single-center survey of liver and kidney transplant recipients 2007
  • Virological response and safety outcomes in therapy naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study.  Journal of Hepatology.  47:51-59. 2007
  • Current and future hepatitis C therapies..  Archives of Medical Research.  38:678-690. 2007
  • Is early recurrence of hepatitis C associated with biliary anastomotic stricture after liver transplantation? 2007
  • Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis..  Clinical Gastroenterology and Hepatology.  5. 2007
  • A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.  Antiviral Therapy.  11:35-45. 2006
  • Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation.  Digestive Diseases and Sciences.  51:1226-1229. 2006
  • Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease.  Clinical Gastroenterology and Hepatology.  4:1162-1169. 2006
  • Global transcriptional effects of PEG-IFN-alfa on peripheral blood cells obtained from patients with chronic hepatitis C.  Hepatology Research.  36:277-287. 2006
  • Impact of implementation of the MELD Scoring system on the prevalence and incidence of chronic liver disease following liver transplantation.  Liver Transplantation.  12:754-761. 2006
  • Longterm Care of the Liver Transplant Recipient.  Therapy of Digestive Disorders.  2006
  • Viral hepatitis: manifestations and management strategy.  Hematology.  375-380. 2006
  • Clinical and financial impact of obesity on the outcome of liver transplantation..  Transplantation proceedings.  38. 2006
  • Combined hepatic resection and radiofrequency ablation for multiple hepatic adenomas..  Journal of Gastroenterology and Hepatology.  21:1351-1354. 2006
  • Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation..  Liver Transplantation.  12:51-57. 2006
  • Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis..  Liver Transplantation.  12:306-309. 2006
  • Pathogenesis of recurrent hepatitis C after liver transplantation 2005
  • A brief psychological intervention to improve adherence following transplantation.  Annals of Transplantation.  10:52-57. 2005
  • A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients.  Liver Transplantation.  11:941-949. 2005
  • Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C IFN-alpha resistance.  Journal of Interferon & Cytokine Research.  25:528-539. 2005
  • Early Hepatic Stellate Cell Activation Is Associate With Advanced Fibrosis after Liver Transplantation In Recipients With Hepatitis C.  Liver Transplantation.  11:1235-1241. 2005
  • Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation.  Hepatology.  41:72-81. 2005
  • Liver retransplantation: a single-center outcome and financial analysis..  Transplantation proceedings.  37. 2005
  • Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication..  Virology Journal.  2:80. 2005
  • Short recovery time after percutaneous liver biopsy: should we change our current practices?.  Clinical Gastroenterology and Hepatology.  3:926-929. 2005
  • An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection.  Hepatology.  40:1062-1071. 2004
  • Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease.  Hepatology.  40:459-466. 2004
  • Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis.  Laboratory Investigation.  84:332-341. 2004
  • One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection..  Liver Transplantation.  10:1240-1247. 2004
  • Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C..  Liver Transplantation.  10:199-207. 2004
  • Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research..  Liver Transplantation.  10:412-417. 2004
  • CD8+ T cell interaction with the HCV replicon cells: evidence for both cytokine and cell-mediated antiviral activity.  Hepatology.  37:1335-1342. 2003
  • Gene expression associated with IFN alpha antiviral activity in a HCV replicon cell line.  Hepatology.  37:1180-1188. 2003
  • Immunopathogenesis of Viral Hepatitis.  Hepatitis.  1:3-4. 2003
  • Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection..  Liver Transplantation.  9:57-61. 2003
  • Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect..  Higher Education Policy.  38:859-868. 2003
  • Combination Of Interferon Alfa-2b and Ribavirin in liver transplant recipients with histologic recurrent hepatitis C.  Liver Transplantation.  8:1000-1006. 2002
  • Future Drug Development.  Experts Perspectives on Contemporary Clinical Issues in Hepatitis C.  21-24. 2002
  • Interleukin 10 inhibition of nitric oxide biosynthesis involves suppression of CAT-2 transcription.  Nitric Oxide.  6:79-84. 2002
  • Liver transplantation for hepatocellular carcinoma..  Minerva chirurgica.  57:575-585. 2002
  • Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation..  Liver Transplantation.  7:1064-1070. 2001
  • The immunopathogenesis of hepatitis C virus infection..  Clinics in Liver Disease.  5:931-953. 2001
  • Interleukin-12 production in chronic hepatitis C infection.  Journal of Hepatology.  33:169. 2000
  • Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders..  Gastroenterology.  118:655-660. 2000
  • Future options for the management of hepatitis C.  Liver Disease.  19:103-112. 1999
  • The utility of noninvasive serologic markers in the managment of early allograft rejection in liver transplantation recipients 1999
  • Determination of HCV-Specific Bulk CD8(+) Activity in Liver.  Methods in Molecular Medicine.  19:431-438. 1998
  • Intrahepatic HCV-specific CTL activity and response to interferon therapy in chronic HCV.  Hepatology.  28:225-230. 1998
  • Pathogenesis of chronic hepatitis C virus infection..  Therapies of Viral Hepatitis.  3:25-35. 1998
  • Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection.  Clinics in Liver Disease.  515-528. 1997
  • Serum interleukin 4 and interleukin 10 in patients with chronic hepatitis C virus infection.  Journal of Hepatology.  26:471-478. 1997
  • The role of hepatits C virus-specific cytotoxic T lymphocytes in chronic hepatits C.  Journal of Immunology.  158:1473-1481. 1997
  • Transforming growth factor- 1 in chronic hepatitis C.  Journal of Viral Hepatitis.  4:29-35. 1997
  • Treatment of chronic hepatitis C.  Comprehensive Therapy.  23:269-276. 1997
  • Anti-GOR in chronic HCV patients with membranoproliferative glomerulonephritis.  Journal of Hepatology.  24:248. 1996
  • Host immune response in hepatitis C virus infection.  Viral Hepatitis Reviews.  2:37-48. 1996
  • Alpha-Glutathione S-transferase as a marker of hepatocellular damage in chronic hepatitis C virus infection.  American Journal of Clinical Pathology.  104:193-198. 1995
  • Variations of hepatitis C virus NS5B sequence (nucleotides 8261-8566) do not correlate with response to interferon-alpha therapy.  Journal of Viral Hepatitis.  2:285-292. 1995
  • Host immune response in pathogenesis of hepatitis C.  Experts Perspectives on Contemporary Clinical Issues in Hepatitis C. 

featured in

• IMPACT! UF and FSU researchers are collaborating to tackle youth concussions
• UF delivers promise of personalized medicine to heart patients
• UF receives $1.25 million to advance clinical research and personalized medicine

principal investigator on

• ...Oral Antivirals...With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic...  awarded by Gilead Sciences 2011 -
• ...Psi-7977 in Combination with Bms-790052 with or Without Ribavirin in Treatment of Naive Subjects Chronically Inf...  awarded by Bristol-Meyers Squibb 2011 - 2013
• 2 Stg Mlt-Ctr Opn-Lbl Stdy of Mapatumumab (Ýhgs1012¨, Fully-Human Monoclonal Antibody to Trail-R1) in Comb C Sorafenib..  awarded by Human Genome Sciences, Inc 2008 - 2012
• A 12 Week Multi-Ctr Dbl-Bld Rndmzd Plcb-Cntrl Dose Response Stdy of the Anti-Viral Effct of Oral Ut-231b in Non-Cicchoti  awarded by United Therapeutics Corporation 2004 - 2006
• A Long Term Follow-Up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored  awarded by Gilead Sciences 2011 - 2013
• A Long Term Follow-Up Registry for Subjects Who Did Not Achiieve a Susstained Virologic Response to Treatment in Gilead-  awarded by Gilead Sciences 2011 - 2013
• A Multi-Center Double Blind Parallel Group Randomized Placebo Controlled Dose Ranging Study to Investigate the Safety...  awarded by Pharmasset 2009 - 2012
• A Multi-Center, Randomized, Open Label Study to Evaluate Thesafety, Tolerability and Efficacy of Albuferon....  awarded by Human Genome Sciences, Inc 2004 - 2009
• A Multicenter Open Label Randomized Duration Finding Study to Investigate the Safety Tolerability Pharmacokinetics......  awarded by Quintiles, Inc 2011 - 2013
• A Multicentered Double-Blinded Study in Noncirrhotic Patients with Chronic Hepatitis C Who are Non-Responders to Prior  awarded by Sciclone Pharmaceuticals, Inc 2002 - 2006
• A Multicentered Doubleblinded Study in Noncirrhotic Patientsw. Chronic Hepatitis C Who are Nonresponders to Prior Interf  awarded by Sciclone Pharmaceuticals, Inc 2002 - 2007
• A Multidisciplinary and Translational Approach to Hepatobiliary Malignancy  awarded by National Cancer Institute 2010 - 2015
• A Phase 2 Study of Vx-950 in Combination with Peginterferon Alfa-2a (Pegasys)with and Without Ribavirin (Copegus) in .....  awarded by Duke University 2006 - 2010
• A Phase 2, Randomized, Open-Label Study of the Safety, Antiviral Activity, and Pharmacokinetics.....  awarded by American Home Products Wyeth Ayerst Laboratories, Inc. 2006 - 2009
• A Phase 2b Randomized Double Blind Placebo Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With....  awarded by Gilead Sciences 2010 - 2011
• A Phase 2b Study of Bms-790052 in Combinatin with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1  awarded by Bristol-Meyers Squibb 2010 - 2012
• A Phase 2b Study of Bms-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive . .  awarded by Bristol-Meyers Squibb 2010 - 2012
• A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin......  awarded by Vertex Pharmaceuticals 2008 - 2011
• A Phase 3, Multicenter Randomized Active-Controlled Study to Investigate the Dafety and Efficacy of Psi-7977.....  awarded by Quintiles, Inc 2012
• A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy Safety and Tolerability of Albumin.......  awarded by Human Genome Sciences, Inc 2006 - 2009
• A Phase 3b Study of 2 Tx Durations of Telaprevir, Pegasys, and Copegus in Treatment-Naive and Prior Relapser Subjects  awarded by Vertex Pharmaceuticals 2011 - 2012
• A Phase Ii Study of Telaprevir (Vx-950) in Combination with Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus).....  awarded by Vertex Pharmaceuticals 2007 - 2009
• A Phase Ii, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the Hcv Po  awarded by Hoffmann La Roche Inc Roche Lab 2007 - 2010
• A Phase Ii,... of the Hcv Polymerase Inhibitor Prodrug (Ro4588161) When Given in Conmibation with Pagasys with or Withou  awarded by Hoffmann La Roche Inc Roche Lab 2006 - 2010
• A Phase Iib Clinical Trial to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine (Nm283) in ...  awarded by Idenix Pharmaceuticals 2005 - 2008
• A Randomized Double Blind Multicenter Study Comparing the Safety and Efficacy of Viramindine to Ribavirin in ....  awarded by Pharmaceutical Product Development, Inc 2003 - 2006
• A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects  awarded by Vertex Pharmaceuticals 2008 - 2010
• A Randomized, Double-Blind, Placebo-Controlled, Phase 111 Trial of 2 Regimens of Telaprevir (With and Without Delayed.  awarded by Tibotec BVBA 2008 - 2010
• A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics . . .  awarded by Abbott Laboratories 2011 - 2012
• A Trial of Cts-1027 in Interferon -Naive Hepatitis C Patients  awarded by SC Liver Research Consortium 2009 - 2011
• A Trial of Zadaxin with Trans Arterial Chemoembolization (Tace) in the Treatment of Adult Patients . . . Phase Ii  awarded by Sciclone Pharmaceuticals, Inc 2003 - 2007
• Aasld 2007 Advanced Hepatology Fellowship - Virginia Clark  awarded by American Association for the Study of Liver Diseases 2007 - 2008
• Aasld 2008 Np/Pa Fellowship  awarded by American Association for the Study of Liver Diseases 2008 - 2009
• Aasld 2008 Np/Pa Fellowship for Jen-Jun Pan  awarded by American Association for the Study of Liver Diseases 2008 - 2009
• Aasld 2009 Np/Pa Fellowship for Patrick Horne  awarded by American Association for the Study of Liver Diseases 2009 - 2010
• Aasld-2005 Np/Pa Clinical Hepatology Fellowship Program  awarded by American Association for the Study of Liver Diseases 2005 - 2006
• An Open Label Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmocokinetics and Antiviral Activity.  awarded by Abbott Laboratories 2012 - 2013
• An Open Label Randomized Study to Evaluate the Efficacy and Safety of Abt-450 with Ritonavir (Abt-450/R) in Combination  awarded by Abbott Laboratories 2012 - 2013
• An Open Label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a(Pegasys)as Monotherapy or in Combination.....  awarded by Hoffmann La Roche Inc Roche Lab 2007 - 2010
• An Open-Label Pilot...Abt-450 with Ritonavir (Abt_450/R) Doesed in Combination with Abt-33 and Ribavirin (Rbv) in Treatm  awarded by Abbott Laboratories 2011 - 2013
• An Open-Label, Multicenter Protocol Proving Pegylated Inter-Feron Alfa-2a (Pegasys) As Monotheraphy or in Combination...  awarded by Hoffmann La Roche Inc Roche Lab 2004 - 2009
• Basic Research Training in Gastroenterology and Hepatology  awarded by National Institute of Diabetes and Digestive and Kidney Diseases 2005 - 2006
• Basic Research Training in Gastroenterology and Hepatology  awarded by National Institute of Diabetes and Digestive and Kidney Diseases 2007 - 2011
• Basic Research Training in Gastroenterology and Hepatology  awarded by National Institute of Diabetes and Digestive and Kidney Diseases 2006 - 2007
• Dose-Ranging Study of Viramidine in Combination with Pegasysin Treatment-Naive Subjects with Chronic Hepatitis C  awarded by RibaPharm 2002 - 2005
• Hcv Target: Hepatitis C Therapeutic Registry and Research Network  awarded by Kadmon, Inc 2011 - 2021
• Hcv-Target Funding Source: Vertex  awarded by Vertex Pharmaceuticals 2012
• Hcv-Target: Hepatitis C Therapeutic Tegistry and Research Network a Longitudianl, Observational Study (Funding Source)  awarded by Genentech, Inc 2012 - 2013
• Lawton Family Liver Research - 008386  awarded by University of Florida Foundation, Inc 2005 - 2016
• Liver Serodiagnostic Panel Results with Histological Evaluations of Liver Inflammation and Fibrosis in Patients.........  awarded by Banyan Biomarkers, Inc. 2008 - 2010
• Mechanisms of Innate and Adaptive Immunity in Hcv  awarded by NIH Bethesda 2005 - 2010
• Mltpl-Ctr Obs-Blnd Rndmzd Plcb-Ctrl Sgl E Mlt Ascending Dosestdy to Inv Pharmkin/Pharmdyn/Saf/Tol/Food Eff of Ro5024048  awarded by Pharmasset 2007 - 2009
• Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery  awarded by Bayer Healthcare Pharmaceuticals 2010 - 2013
• Nv17317: Randmzd, Mltctr, Open Label, Phase Iv Study Evalu- Ating the Efficacy and Safety of 16-Wk V 24-Wk Treatment Of  awarded by Hoffmann La Roche Inc Roche Lab 2003 - 2006
• Opn-Lbl Rdmzd 5-Arm Prl-Grp Stdy of Eff on Viral Kinetics, Saf and Pharmocokinetics of Diff Dosing Reg of Debio 025...  awarded by Debio Pharm Group 2007 - 2011
• P7977-0422 Multi-Center...Assessment of Psi-7977 in Patientswith Hcv Genotypes 2 or 3  awarded by Pharmasset 2010 - 2013
• Phase 1 Stdy to Eval the Saf, Tolerability, and Pharmacokin of Escalating Dose of Albuferon Recombinant Human Albumin-  awarded by Human Genome Sciences, Inc 2001 - 2006
• Phase 2 Randomized, Open-Label Study of Gs-5885 Administered Concomitantly with Gs-9451, Tegobuvir and Ribavirin......  awarded by Gilead Sciences 2011 - 2012
• Phase Ii Comparison of Fibroscan with Histological Evaluations of Liver Fibrosis in Patients with Hepatitis B and C.......  awarded by Echosens 2007 - 2009
• Phase Iv Pilot Study Evaluating Pegasys 180 Ug or 270 Ug in Combination with Copegus Doses of 1200 Mg or 1600 Mg On  awarded by Hoffmann La Roche Inc Roche Lab 2004 - 2006
• Phs2 Rdmzd 2blnd Plcb-Ctrl Stdy of Nitazoxanide in Comb C Peginterferon Alpha2a and Ribovirin in Pt C Hep C Who Have...  awarded by Romark Laboratories 2007 - 2009
• Prospctv Rndmzd Multictr Opn-Lbl Compar Sfty and Effic Stdy Ofprophylactically Admnstre Pegylated Interferon.. Ml18124  awarded by Hoffmann La Roche Inc Roche Lab 2004 - 2009
• Prospective Observational Study on Predictors of Early-On Treatment Response and Sustained Virological Response In...  awarded by Hoffmann La Roche Inc Roche Lab 2008 - 2010
• Quantum: an International Multicenter Blinded Randomized Study to Investigate Safety Tolerability Pharmacokinetics......  awarded by Pharmasset 2011 - 2012
• Randomized, Controlled Phase 2a/B Study of the Efficacy and Safety of Peg-Ril-29 Administered in Combination With.......  awarded by Zymogenetics 2010 - 2012
• Res and Dev Gastroenterology - 002739  awarded by University of Florida Foundation, Inc 2005 - 2015
• Testing the Efficacy of Jvrs-100 on Hcv Replication and Immune Function  awarded by Juvaris Biotherapeutics 2007 - 2008
• UF Clinical and Translational Science Award  awarded by National Center for Research Resources 2009 - 2014
• UF Clinical and Translational Science Award: Gender Diff Intmjd: Influence of Genetic, Hormones and Inflammatory Resp  awarded by National Center for Research Resources 2009 - 2014
• Vx-222 and Telaprevir in Comb With/Without Peginterferon- Alpha-2a (Pegasys) and Ribavirin (Copegus)...  awarded by Vertex Pharmaceuticals 2010 - 2013
• Vx-950-107 a Phase Ii Roll Over Protocol of Telaprevir 107 a Phase Ii Roll Over Protocol of Telaprevir (Vx905).....  awarded by Vertex Pharmaceuticals 2007 - 2011
• Wo 2: Retrospective Data-Collection Study to Investigate The12-Week, End-Of-Treatment (Eot) and Sustained Viral Response  awarded by Pharmasset 2008 - 2010
• Womens Ischemia Syndrome Evaluation (Wise) and Women Take Heart (With) Studies Bank  awarded by National Center for Research Resources 2009 - 2014

co-principal investigator on

• Whole Transcriptome Sequencing of Non-Small-Cell Lung Cancer (Nsclc)  awarded by State University System Of Florida Board Of Governors 2006 - 2015

teaching activities

• BCC7110 Fall 2009 7236 BCC7110 Fall 2009 7236
• BCC7110 Fall 2010 7236 BCC7110 Fall 2010 7236
• BCC7111 Fall 2009 8637 BCC7111 Fall 2009 8637
• BCC7111 Fall 2010 8637 BCC7111 Fall 2010 8637
• BMS6300C Fall 2008 8591 BMS6300C Fall 2008 8591
• BMS6300C Fall 2009 8591 BMS6300C Fall 2009 8591
• BMS6300C Fall 2010 8591 BMS6300C Fall 2010 8591
• BMS6300C Fall 2011 8591 BMS6300C Fall 2011 8591
• BMS6834 Summer 2009 8865 BMS6834 Summer 2009 8865
• GMS6905 Fall 2008 0202 GMS6905 Fall 2008 0202
• GMS6905 Spring 2009 1921 GMS6905 Spring 2009 1921
• GMS6905 Spring 2011 1921 GMS6905 Spring 2011 1921
• GMS6910 Summer 2009 9186 GMS6910 Summer 2009 9186
• GMS6971 Summer 2009 8120 GMS6971 Summer 2009 8120
• GMS6971 Summer 2011 8120 GMS6971 Summer 2011 8120
• GMS7093 Summer 2009 4415 GMS7093 Summer 2009 4415
• GMS7980 Fall 2008 0244 GMS7980 Fall 2008 0244
• GMS7980 Fall 2009 0244 GMS7980 Fall 2009 0244
• GMS7980 Spring 2009 2753 GMS7980 Spring 2009 2753
• GMS7980 Spring 2010 2753 GMS7980 Spring 2010 2753
• MEL7948 Fall 2008 2356 MEL7948 Fall 2008 2356
• MEL7948 Fall 2009 2356 MEL7948 Fall 2009 2356
• MEL7948 Fall 2010 2356 MEL7948 Fall 2010 2356
• PAS5160 Spring 2009 894 PAS5160 Spring 2009 894
• PAS5160 Spring 2010 0809 PAS5160 Spring 2010 0809

education

• M.D. in Medicine, State University of New York at Syracuse 1990
• B.A. in Unknown, Dartmouth College 1986

fax

mailing address

• PO Box 100219

  Gainesville

  FL

  32610-0219